vs
Apellis Pharmaceuticals, Inc.（APLS）与威伯科（CVGI）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是威伯科的1.3倍（$199.9M vs $154.8M），威伯科同比增速更快（-5.2% vs -5.9%），威伯科自由现金流更多（$8.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -10.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
威伯科控股曾是总部位于美国的重型商用车零部件供应商，主打电子制动、稳定性控制、悬挂及传动自动化系统，产品广泛应用于卡车、巴士、挂车以及非道路作业车辆等各类商用车领域，是商用车行业重要的零部件提供商。
APLS vs CVGI — 直观对比
营收规模更大
APLS
是对方的1.3倍
$154.8M
营收增速更快
CVGI
高出0.7%
-5.9%
自由现金流更多
CVGI
多$23.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
-10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $154.8M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 9.7% |
| 营业利润率 | -25.6% | -1.2% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -5.2% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCVGI
| Q4 25 | $199.9M | $154.8M | ||
| Q3 25 | $458.6M | $152.5M | ||
| Q2 25 | $178.5M | $172.0M | ||
| Q1 25 | $166.8M | $169.8M | ||
| Q4 24 | $212.5M | $163.3M | ||
| Q3 24 | $196.8M | $171.8M | ||
| Q2 24 | $199.7M | $193.7M | ||
| Q1 24 | $172.3M | $194.6M |
净利润APLSCVGI
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-7.1M | ||
| Q2 25 | $-42.2M | $-4.8M | ||
| Q1 25 | $-92.2M | $-4.3M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $9.5M | ||
| Q2 24 | $-37.7M | $-1.6M | ||
| Q1 24 | $-66.4M | $2.9M |
毛利率APLSCVGI
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 9.6% | ||
| Q2 24 | — | 10.6% | ||
| Q1 24 | — | 11.9% |
营业利润率APLSCVGI
| Q4 25 | -25.6% | -1.2% | ||
| Q3 25 | 48.7% | -0.7% | ||
| Q2 25 | -18.6% | 0.5% | ||
| Q1 25 | -50.0% | 0.8% | ||
| Q4 24 | -12.3% | -3.2% | ||
| Q3 24 | -24.0% | -0.6% | ||
| Q2 24 | -14.7% | 0.5% | ||
| Q1 24 | -36.0% | 2.3% |
净利率APLSCVGI
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -4.6% | ||
| Q2 25 | -23.6% | -2.8% | ||
| Q1 25 | -55.3% | -2.5% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 5.5% | ||
| Q2 24 | -18.9% | -0.8% | ||
| Q1 24 | -38.5% | 1.5% |
每股收益（稀释后）APLSCVGI
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | $-0.05 | ||
| Q1 24 | $-0.54 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $104.9M |
| 股东权益账面价值 | $370.1M | $133.4M |
| 总资产 | $1.1B | $391.7M |
| 负债/权益比越低杠杆越低 | — | 0.79× |
8季度趋势，按日历期对齐
现金及短期投资APLSCVGI
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSCVGI
| Q4 25 | — | $104.9M | ||
| Q3 25 | — | $108.2M | ||
| Q2 25 | — | $118.2M | ||
| Q1 25 | — | $117.4M | ||
| Q4 24 | — | $135.5M | ||
| Q3 24 | — | $128.8M | ||
| Q2 24 | — | $142.0M | ||
| Q1 24 | $93.1M | $155.7M |
股东权益APLSCVGI
| Q4 25 | $370.1M | $133.4M | ||
| Q3 25 | $401.2M | $136.5M | ||
| Q2 25 | $156.3M | $142.6M | ||
| Q1 25 | $164.2M | $136.7M | ||
| Q4 24 | $228.5M | $135.6M | ||
| Q3 24 | $237.1M | $179.3M | ||
| Q2 24 | $264.3M | $169.6M | ||
| Q1 24 | $266.7M | $175.5M |
总资产APLSCVGI
| Q4 25 | $1.1B | $391.7M | ||
| Q3 25 | $1.1B | $400.3M | ||
| Q2 25 | $821.4M | $429.8M | ||
| Q1 25 | $807.3M | $419.8M | ||
| Q4 24 | $885.1M | $424.6M | ||
| Q3 24 | $901.9M | $495.3M | ||
| Q2 24 | $904.5M | $503.2M | ||
| Q1 24 | $831.9M | $509.2M |
负债/权益比APLSCVGI
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.79× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 1.00× | ||
| Q3 24 | — | 0.72× | ||
| Q2 24 | — | 0.84× | ||
| Q1 24 | 0.35× | 0.89× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $12.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 5.6% |
| 资本支出强度资本支出/营收 | 0.1% | 2.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $34.0M |
8季度趋势，按日历期对齐
经营现金流APLSCVGI
| Q4 25 | $-14.2M | $12.3M | ||
| Q3 25 | $108.5M | $-1.7M | ||
| Q2 25 | $4.4M | $18.9M | ||
| Q1 25 | $-53.4M | $15.2M | ||
| Q4 24 | $19.4M | $-26.6M | ||
| Q3 24 | $34.1M | $-17.1M | ||
| Q2 24 | $-8.3M | $12.6M | ||
| Q1 24 | $-133.0M | $-2.4M |
自由现金流APLSCVGI
| Q4 25 | $-14.3M | $8.7M | ||
| Q3 25 | $108.3M | $-3.5M | ||
| Q2 25 | $4.4M | $17.4M | ||
| Q1 25 | $-53.4M | $11.4M | ||
| Q4 24 | $19.3M | $-30.6M | ||
| Q3 24 | — | $-20.3M | ||
| Q2 24 | $-8.4M | $6.4M | ||
| Q1 24 | $-133.3M | $-7.4M |
自由现金流率APLSCVGI
| Q4 25 | -7.1% | 5.6% | ||
| Q3 25 | 23.6% | -2.3% | ||
| Q2 25 | 2.5% | 10.1% | ||
| Q1 25 | -32.0% | 6.7% | ||
| Q4 24 | 9.1% | -18.7% | ||
| Q3 24 | — | -11.8% | ||
| Q2 24 | -4.2% | 3.3% | ||
| Q1 24 | -77.3% | -3.8% |
资本支出强度APLSCVGI
| Q4 25 | 0.1% | 2.3% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 1.9% | ||
| Q2 24 | 0.0% | 3.2% | ||
| Q1 24 | 0.2% | 2.6% |
现金转化率APLSCVGI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.79× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
